Summary: Xpert enables rapid diagnosis of childhood TB on two NPA (nasopharyngeal aspirates) or two induced sputum (IS) specimens with sensitivity of 65% and 71% respectively and high specificity. Two IS provide a higher yield than 2 NPAs for culture confirmation.
A c c e p t e d M a n u s c r i p t 3 Diagnosis of pulmonary tuberculosis (PTB) in children remains challenging due to nonspecific clinical or radiological signs and lack of capacity to obtain appropriate specimens. 1 Moreover as childhood TB is paucibacillary, diagnosis using smear microscopy is usually negative. However, recent advances in specimen collection and diagnostic testing have shown that a microbiologic diagnosis can be effectively made. 2 Repeated induced sputum (IS) specimens are feasible and effective for culture confirmed diagnosis of PTB in children. [3] [4] [5] We recently reported that rapid diagnosis of PTB in children using Xpert MTB/RIF (Xpert, Cepheid, CA, USA), for Mycobacterium tuberculosis and resistance to rifampicin, could be effectively done using IS specimens. 6 Two Xpert tests detected 76% of culture-confirmed cases, twice the yield from smear, with a specificity of 99%. 6 Rifampicin resistance was reliably detected. Results were faster than liquid culture. 6 These provide pediatric evidence to support WHO recommendations that Xpert replace smear as the initial diagnostic test in suspected HIV-associated TB or multidrug resistant TB and as a follow-on test in settings where these are less of a concern.
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The implementation of Xpert in children is constrained by limited capacity to perform IS.
Use of a nasopharyngeal aspirate (NPA) is attractive as this can be easily and non-invasively obtained, with lower risk of nosocomial transmission. However, a study of Peruvian children comparing 2 NPAs with 2 gastric aspirates (GAs) found that NPAs detected only 50% of culture positive cases. 8 Moreover, an in-house polymerase chain reaction (PCR) had insufficient sensitivity or specificity for clinical use. 8 However, no comparison with IS was done. A small Ugandan study reported promising results for culture and PCR on NPAs from A c c e p t e d M a n u s c r i p t 5
Response to treatment was assessed using clinical features and chest radiograph at treatment completion.
Written, informed consent was obtained from a parent or legal guardian. The study was approved by the Ethics Committee of the Faculty of Health Sciences, University of Cape Town.
Nasopharyngeal aspirate and sputum induction
A NPA was obtained before IS. Two drops of sterile saline were instilled into each nostril and the nasopharynx suctioned using a sterile catheter with a mucus trap. A second NPA was obtained the following day or a minimum of 4 hours after the first IS.
Sputum induction was done at least 30 minutes after an NPA, following a 2-3 hour fast by a trained research nurse as has been previously described. 3 A second IS was obtained the following day or a minimum of 4 hours after the first specimen. Pulse oximetry was done throughout the procedure and 30 minutes thereafter.
NPA and IS specimens were processed within 2 hours of collection in an accredited laboratory by trained technologists, using standardised protocols. For both specimens, following decontamination with N-acetyl-L-cysteine and sodium hydroxide (1·0% final concentration), centrifuged deposits were re-suspended in 1·5ml of phosphate buffer. A drop of sediment was used for fluorescent acid-fast smear microscopy. For Xpert, 1·4ml of specimen reagent was added to 0·7 mL of re-suspended sputum/NPA pellet and processed as previously reported. 10 Automated liquid culture (BACTEC MGIT, Becton Dickinson , , USA) was performed using 0·5ml of re-suspended pellet. Cultures were incubated for 6
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A c c e p t e d M a n u s c r i p t 6 weeks. Positive cultures were identified by acid-fast staining followed by MTBDRplus testing (Hain Lifesciences, Hehren, Germany) to confirm M. tuberculosis and rifampicin and isoniazid resistance. 13 Staff performing Xpert were blind to culture results.
If Xpert identified rifampicin resistance, the corresponding cultured isolate also underwent phenotypic resistance testing by automated liquid MGIT culture.
Definition of TB disease
Children were categorised as 'Definite TB' (culture positive on any specimen for M.
tuberculosis), 'Not TB' (documented resolution of symptoms and signs at follow up in children who didn't receive TB treatment) or 'Possible TB' (all others).
Analysis
The primary reference standard was a positive culture for M. tuberculosis from an IS or NPA.
We excluded children without at least one paired IS/NPA specimen or children with extrapulmonary TB. We separately analysed patients with at least one paired IS and NPA sand those with two paired specimens. For the former, we used a positive culture from any NPA or IS specimen as the reference standard to determine the sensitivity of a single Xpert Where results for RIF susceptibility testing were available from culture (followed by 
DISCUSSION
This study has shown that Xpert on two NPA specimens detected almost two thirds of culture-confirmed TB in young children hospitalized with suspected PTB, with very high specificity. The number of cases detected by Xpert on repeat NPAs was similar to that on two IS specimens, and was more than double that detected by smear microscopy. A single Xpert on a NPA detected almost all smear-positive cases. This study contributes further evidence for the usefulness of Xpert for diagnosis of childhood TB and for replacement of smearmicroscopy. This is also the first study to show the usefulness of Xpert using NPAs.
The yield from Xpert on NPAs represents an important potential advance in diagnosis of childhood TB. The sensitivity on NPAs was higher than reported for other nucleic acid amplification tests 8, 9 possibly due to improved accuracy of Xpert. 10 Performing Xpert on both IS and NPAs detected 80% of culture confirmed cases; however, obtaining four specimens is likely to be too costly and labour intensive to be feasible in resource poor settings.
Microbiologic diagnosis in children has been hampered by inability to perform IS and by paucibacillary disease, making smear a poor tool for diagnosis. Health care workers have not been widely trained in IS and facilities for induction frequently don't exist. 5 NPAs may therefore enable diagnosis as specimens can be easily and non-invasively obtained. Our findings are consistent with other paediatric studies from Uganda, Yemen and Peru, reporting that NPAs may be useful for diagnosis. 8, 9, 14, 15 These studies, using culture and PCR on NPA and other specimens, have shown an appreciable yield similar or less than that from IS or GA. In contrast to our study, these studies enrolled older children (median age 3-5 years), Approximately a third of children had culture confirmed TB, but negative Xperts. In these children, IS provided a higher yield for culture than NPAs. A study from Yemen also showed superior sensitivity of IS over NPA specimens for culture. 14 Sputum induction has been shown to be safe, effective and feasible for diagnosis of PTB in young children in several studies, including primary care settings. [3] [4] [5] [6] 9 Increasing availability and improved affordability of Xpert enables rapid confirmation of TB and rifampicin resistance close to the point of care. Therefore upscaling of capacity for IS in children should be a priority.
However, in the absence of such capacity and in settings where culture is not possible, Xpert testing of two NPAs should be recommended as the first line investigation for children with suspected PTB.
Xpert results were available on the same day, shorter than the time for culture. Lack of treatment or delayed initiation of therapy remains a major challenge with studies reporting that 20% to 47% of children with culture-confirmed TB are discharged from hospital without commencing TB therapy. [16] [17] [18] Disease progression may occur rapidly and tracing children after discharge may be difficult. 16 Use of Xpert enables prompt initiation of TB therapy, so minimising the number of children who may go untreated or receive delayed treatment.
Approximately half the children were diagnosed with possible TB, of whom 76% were treated based on clinical diagnosis. Children who weren't treated and who were lost to follow-up were included in the possible TB group, as response in the absence of TB treatment couldn'tbe evaluated. A minority of those with possible TB were Xpert positive;
these probably represent true cases as almost all were treated for TB with good clinical response. 19 A better diagnostic test to distinguish those children who have TB amongst the possible TB cases is urgently needed. However, the absence of a reference standard other than culture makes evaluation of any new test in children with possible TB challenging.
Limitations of this study include small numbers of HIV-infected children with cultureconfirmed disease, few rifampicin-resistant cases and the need to split NPA and sputum sediment between culture and Xpert. We split NPA and sputum pellets to directly compare culture and Xpert on the same specimen. Although Xpert is designed for use directly on specimens, adult studies have demonstrated equivalent performance when used directly on a specimen or on a pellet. 10 We did not compare GLs as several studies have demonstrated the superiority of IS over GL for mycobacterial culture in hospitalised children with suspected TB. [3] [4] [5] [20] [21] [22] The generalizability of results to children with less severe illness requires further study. Further, cost efficacy analyses of Xpert are needed. However, a recent study suggests that replacement of smear microscopy with Xpert in adults is highly cost effective. 23 Xpert may be especially suited to resource constrained settings where culture is unlikely to be routinely available due to cost and complexity of mycobacterial culture.
Conclusion
Xpert provides a useful test for rapid diagnosis of TB in children on repeated NPA or IS specimens. IS is preferable for culture confirmation; capacity for IS in children must be increased. Xpert testing on two NPAs should be recommended in children in settings where IS and mycobacterial culture are not possible. 
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